Status:
UNKNOWN
Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
The management of patients with a selective IgA deficiency currently consists of symptomatic treatment with treatment of infections by occasional or prolonged antibiotic therapy, immunosuppressive tre...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Major subject (≥18 years old)
- Subject treated at the HUS, with a primary selective IgA deficiency, considered as definitive (IgA concentration \< 0.07g/L or total absence of IgA on immunofixation) or as probable (IgA concentration lower than two standard leads to standard for age) with no other humoral immunodeficiency and no other cause of decreased gammaglobulins 01/01/2005 to 01/31/2022.
- Subject having not expressed, after being informed, their opposition to the reuse of their data for the purposes of this research.
- Exclusion criteria:
- . Subject who expressed their opposition to participating in the study
Exclusion
Key Trial Info
Start Date :
April 9 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06125457
Start Date
April 9 2022
End Date
December 31 2023
Last Update
December 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'Immunologie Clinique - Médecine Interne - CHU de Strasbourg - France
Strasbourg, France, 67091